Self-initiation of antiretroviral therapy in the developing world: The involvement of private pharmacies in an HIV program

Drug, Healthcare and Patient Safety

Volumn 4, Issue 1, 2012, Pages 27-31

  Minzi, Omary Mashiku ^a   Buma, Deus ^a,b   Kagashe, Godeliver A ^b  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b MUHIMBILI NATIONAL HOSPITAL   (Tanzania)

Author keywords

Antiretroviral drugs; ART na ve patients; Dispensing practices

Indexed keywords

EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ASSESSMENT; CROSS-SECTIONAL STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MARKETING; DRUG USE; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FEMALE; GROUPS BY AGE; HEALTH CARE ACCESS; HEALTH PROGRAM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HOSPITAL PHARMACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OCCUPATION; ORGANIZATION AND MANAGEMENT; PATIENT ATTITUDE; PRESCRIPTION; PRIVATE PHARMACY; SELF MEDICATION; TANZANIA;

EID: 84859526111     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S23653     Document Type: Article

References (19)

1. UNAIDS. Report on the Global AIDS epidemic. New York: UNAIDS; 2002.
2. World Health Organization. Scaling up antiretroviral therapy in resourcelimited settings. Guidelines for a public health approach. Geneva, Switzerland: World Health Organization; 2003.
3. Foisy MM, Gough K, Quan CM, Harris K, Ibanez D, Phillips A. Hospitalization due to adverse drug reactions and drug interactions before and after HAART. Can J Infect Dis. 2000;11:193-201.
4. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170:667-672.
5. Wester CW, Okezie OA, Thomas AM, Bussmann H. Higher-thanexpected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. AIDS. 2007;46:318-322.
6. Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical diseases progression to AIDS or death. HIV Med. 2007;8:96-104.
7. Rodriguez-Arenas MA, Jarrin I, del Amo J, et al. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injection drug users in Spain. AIDS Res Hum Retroviruses. 2006;22:715-723.
8. Rattan A, Kumar A. Antibiotics-use and misuse. J Acad Hosp Adm. 1995;7:19-22.
9. Stenson B, Syhakhang L, Ericksson B, Tomson G. Real world pharmacy: assessing the quality of private pharmacy practice in Lao People's Democratic Republic. Soc Sci Med. 2001;52:393-404.
10. Goodman C, Kachur SP, Abdulla S, Bloland P, Mills A. Drug shop regulation and malaria treatment in Tanzania-why do shops break the rules, and does it matter? Health Policy Plan. 2007;22:393-403.
11. Goel P, Ross-Degnan D, Berman P, Soumerai S. Retail pharmacies in developing countries: a behavior and intervention framework. Soc Sci Med. 1996;42:1155-1161.
12. Rawlings MK, Smith KY. Recognizing and managing common toxicities in patients receiving antiretroviral therapy. AIDS. 2004;14:12-15.
13. Wood E, Montaner JS, Yip B, Tyndall MW. Adherence and plasma HIV RNA responses to HAART among HIV-1 infected injection drug users. CMAJ. 2003;169:656-661.
14. Minzi O, Ngaimisi E. Bioanalytical method for determination of nevirapine in-vivo in resource constrained laboratories. J Chem Pharm Res. 2010;2:431-439.
15. Rendón A, Núñez M, Jiménez-Nácher I, González de Requena D, González-Lahoz J, Soriano V. Clinical benefit of interventions driven by therapeutic drug monitoring. HIV Med. 2005;6:360-365.
16. de Maat MM, Huitema AD, Mulder JW, et al. Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care. Ther Drug Monit. 2003;25:367-373.
17. Wit FW, Kesselring AM, Gras L, et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin Infect Dis. 2008;46:933-940.
18. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis. 2006;6:280-287.
19. Knobel H, Guelar A, Montero M, Carmona A, Luque S, González A. Risk of side effects associated with the use of nevirapine in treatmentnaïve patients, with respect to gender and CD4 cell count. HIV Med. 2008;9:14-18.